Cerebrospinal fluid: A specific biofluid for the biosensing of Alzheimer's diseases biomarkers

Mirzaie A., Nasrollahpour H., Khalilzadeh B., Jamali A. A., Spiteri R. J., Yousefi H., ...More

TrAC - Trends in Analytical Chemistry, vol.166, 2023 (SCI-Expanded) identifier

  • Publication Type: Article / Review
  • Volume: 166
  • Publication Date: 2023
  • Doi Number: 10.1016/j.trac.2023.117174
  • Journal Name: TrAC - Trends in Analytical Chemistry
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Analytical Abstracts, Chemical Abstracts Core, Chimica, Compendex, EMBASE, Food Science & Technology Abstracts, DIALNET
  • Keywords: Alzheimer's diseases, Amyloid beta, Biosensor, Cerebrospinal fluid, Tau protein
  • Yıldız Technical University Affiliated: Yes


Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder with an irreversible, progressive, and untreatable nature that causes progressive deterioration, loss of neurons, and cognitive and behavioral decline. An exponential growth of AD is expected in the forthcoming decades. Studies show that amyloid β (Aβ) and Tau proteins are two key biomarkers of AD. Abnormality in Aβ and Tau levels in biofluids - especially cerebrospinal fluid (CSF) - is directly related to AD incidence and progress. Hence, developing sensitive, affordable, and reliable methods for screening and evaluating these biomarker levels is helpful in early diagnosis, tracking, and treatment of AD. This article scrutinizes the possible effect of Alzheimer's condition on CSF. Following a comprehensive summary of biosensors, the latest developed biosensors are discussed for the detection of Aβ and Tau in CSF samples.